gliquidone Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Gliquidone is an anti-diabetic medication in the sulfonylurea class. It is classified as a second-generation sulfonylurea. It is used in the treatment of diabetes mellitus type 2. It is marketed by the pharmaceutical company Boehringer Ingelheim (Germany).   Wikipedia

Chemistry

  • SMILES: COc1ccc2c(c1)C(=O)N(CCc1ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc1)C(=O)C2(C)C
  • InChIKey: LLJFMFZYVVLQKT-UHFFFAOYSA-N
  • Mol. Mass: 527.64
  • ALogP: 3.52
  • ChEMBL Molecule:
    gliquidone  
More Chemistry

Pharmacology

Alternative names

1-cyclohexyl-3-(p-beta-(4,4- dimethyl-2-methoxy-1,3-(2h,4h)-isoquinolinedione- 2-yl)phenethyl)sulfonylurea | ar-df 26 | ardf-26 | beglynor | beglynora | glikvidon | gliquidone | gliquidone calcium | gliquidone, calcium salt | gliquidone monosodium | gliquidone, monosodium salt | gliquidone sodium | glurenor | glurenorm | glycvidon | sanofi synthelabo brand of gliquidone | yamanouchi brand of gliquidone

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (1)


 

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue